164 related articles for article (PubMed ID: 35125336)
1. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
[TBL] [Abstract][Full Text] [Related]
2. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
[TBL] [Abstract][Full Text] [Related]
3. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
4. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
5. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
Dzimitrowicz HE; Wilson LE; Jackson BE; Spees LP; Baggett CD; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman MS; Gross CP; Dinan MA; Wheeler SB
JCO Oncol Pract; 2023 Feb; 19(2):e213-e227. PubMed ID: 36413741
[TBL] [Abstract][Full Text] [Related]
6. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
[TBL] [Abstract][Full Text] [Related]
7. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
[TBL] [Abstract][Full Text] [Related]
8. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
[TBL] [Abstract][Full Text] [Related]
9. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
Chow RD; Long JB; Hassan S; Wheeler SB; Spees LP; Leapman MS; Hurwitz ME; McManus HD; Gross CP; Dinan MA
JNCI Cancer Spectr; 2023 May; 7(3):. PubMed ID: 37202354
[TBL] [Abstract][Full Text] [Related]
10. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.
Miller SM; Wilson LE; Greiner MA; Pritchard JE; Zhang T; Kaye DR; Cohen HJ; Becher RD; Maerz LL; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):635-643. PubMed ID: 34996724
[TBL] [Abstract][Full Text] [Related]
12. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
14. Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma.
Hicks BM; Chun DS; Peacock Hinton S; Hsu CD; Tan HJ; Lund JL
J Geriatr Oncol; 2022 Apr; 13(3):325-333. PubMed ID: 34782282
[TBL] [Abstract][Full Text] [Related]
15. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
[TBL] [Abstract][Full Text] [Related]
16. Residual treatment disparities after oncology referral for rectal cancer.
Morris AM; Billingsley KG; Hayanga AJ; Matthews B; Baldwin LM; Birkmeyer JD
J Natl Cancer Inst; 2008 May; 100(10):738-44. PubMed ID: 18477800
[TBL] [Abstract][Full Text] [Related]
17. Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis.
Onukwugha E; Albarmawi H; Sun K; Mullins CD; Aly A; Hussain A
Urol Oncol; 2018 Jul; 36(7):340.e23-340.e31. PubMed ID: 29724482
[TBL] [Abstract][Full Text] [Related]
18. Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
JCO Oncol Pract; 2022 Sep; 18(9):e1475-e1483. PubMed ID: 35700416
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Approaches for Measuring Adherence and Persistence to Oral Oncologic Therapies in Patients Diagnosed with Metastatic Renal Cell Carcinoma.
Chun DS; Hicks B; Hinton SP; Funk MJ; Gooden K; Keil AP; Tan HJ; Stürmer T; Lund JL
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):893-899. PubMed ID: 35064061
[TBL] [Abstract][Full Text] [Related]
20. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
